Redefining cancer treatment to one day eliminate cancer as a cause of death.

Our ambition is to push the boundaries of science to change the practice of medicine and transform the lives of patients living with cancer.   

To accomplish this, we focus on research and development and our commercial capabilities to deliver a new generation of medicines that have the potential to redefine cancer treatment.

Our approach to Oncology

We follow four strategic priorities to help us achieve our ambition to eliminate cancer as a cause of death:

Focus research on four scientific platforms

We’re targeting the underlying biological drivers of cancer by focusing on four different scientific platforms: Immuno-Oncology, Tumour Drivers and Resistance, DNA Damage Response, and Antibody Drug Conjugates.

Utilise precision medicine in the most prevalent and deadly tumour types

2020欧洲杯体育足球滚球比分We’re concentrating on biomarker-driven indications to dramatically improve five-year survival in five tumour types, including ovarian cancer and non-small cell lung cancer (NSCLC).

Focus on early stages of disease and relapsed patients

Our patient-centric approach focuses on 1) identifying and treating patients earlier in the course of their disease with curative intent; and 2) supporting relapsed and refractory patients by tackling primary or acquired resistance.

Leverage our global footprint

We’re expanding our presence across geographies to deliver timely treatments to patients in the US, UK, Italy, France, Germany, Spain, Japan, and China.

Key disease areas

Among the many different types of cancer that our scientists explore, we are developing new treatment approaches for the following types of cancer:

Our scientific platforms

We’re concentrating on four scientific platforms that we believe show the greatest potential for yielding effective medicines for cancer patients.

  • Immuno-Oncology (IO)

    Activating the body’s own immune system to help fight cancer

  • Tumour Drivers and Resistance (TDR)

    Targeting the genetic mutations and resistance mechanisms that enable cancer cells to evade treatment, survive, and proliferate

  • DNA Damage Response (DDR)

    2020欧洲杯体育足球滚球比分Targeting the DNA repair process to block cancer cells’ ability to reproduce

  • Antibody Drug Conjugates (ADC)

    2020欧洲杯体育足球滚球比分Delivering highly potent cancer-killing agents directly to cancer cells via a linker attached to a targeted antibody

Where science brings us

As part of our commitment to Oncology, we’re constantly working on new and exciting workstreams.
Here are just a few of what we’re up to at the moment.


Lung Ambition Alliance

Lung cancer is at the forefront of AstraZeneca’s research and development focus. Our expanding portfolio aims to provide medicines that can improve outcomes at every stage of the disease. But we know if we are to make meaningful progress for lung cancer patients, we cannot work alone. We have partnered with the International Association for the Study of Lung Cancer (IASLC), the Global Lung Cancer Coalition (GLCC), and Guardant Health to form the Lung Ambition Alliance.  Together we are taking urgent action to double five-year survival in lung cancer globally by 2025 – prioritising research and projects that increase screening, deliver innovative medicine and improve quality care.

2020欧洲杯体育足球滚球比分The great advance of personalised healthcare, in oncology, has been the realisation that some tumours are driven by individual genes. So if you can find out which genes these are, you can develop a medicine that's best for that tumour, and then select patients that are best for that medicine.

Ruth MarchSenior Vice-President of Precision Medicine, R&D Oncology

Collaboration in Oncology

To eliminate cancer as a cause of death, we understand that we cannot work alone. Improving patient outcomes requires a collaborative approach to research and development.

Our Oncology pipeline

Our robust pipeline includes investigational therapies in varied stages of clinical development, from recently approved products to earlier-stage molecules in clinical trials. We aspire to transform the lives of cancer patients, working to eliminate cancer as a cause of death in the future.


Phase III/LCM Projects: refers to assets that are pivotal in Phase II/III or have been submitted for regulatory approval, and may include assets that are launched in one or more major markets (removed when launched in all applicable major markets).

Oncology (as at 29 April 2020)

Phase I

Phase I

  • AZD0466haematological and solid tumours
  • AZD1390glioblastoma
  • AZD4573haematalogical malignancies
  • AZD5153solid tumours, haematological malignancies
  • AZD5991haematalogical malignancies
  • AZD7648haematological and solid tumours
  • AZD9496oestrogen receptor +ve breast cancer
  • Calquence + ceralasertib (AZD6738)haematological malignancies
  • Calquence + danvatirsenhaematological malignancies
  • Imfinzi + adavosertibsolid tumours
  • Imfinzi + Koselugo (selumetinib)solid tumours
  • Imfinzi + RT (platform)CLOVERlocally-advanced head and neck squamous cell carcinoma, non-small cell lung cancer, small-cell lung cancer
  • Imfinzi + tremelimumabsolid tumours
  • Imfinzi + tremelimumab + CTx1st-line pancreatic ductal adenocarcinoma, oesophageal and small cell lung cancer
  • IPH5201solid tumours
  • MEDI1191solid tumours
  • MEDI2228multiple myeloma
  • MEDI5083solid tumours
  • MEDI5395solid tumours
  • oleclumab + TagrissoEGFRm NSCLC

Phase II

Phase II

  • (oleclumab+CTx) or (Imfinzi+oleclumab+CTx)metastatic pancreatic cancer
  • adavosertibovarian cancer, solid tumours
  • AZD2811solid tumours, haematological malignancies
  • AZD4635prostate cancer
  • AZD9833oestrogen receptor +ve breast cancer
  • capivasertibbreast cancer
  • capivasertibprostate cancer
  • Imfinzi (platform)COASTnon small cell lung cancer
  • Imfinzi (platform)NeoCOASTnon small cell lung cancer
  • Imfinzi + AZD4635prostate cancer
  • Imfinzi + AZD5069 orImfinzi + danvatirsenhead and neck squamous cell carcinoma, bladder and NSCLC
  • Imfinzi + FOLFOX + bevacizumabCOLUMBIA 11st-line metastatic microsatellite-stable colorectal cancer
  • Imfinzi + LynparzaBAYOU1st-line unresectable stage IV bladder cancer
  • Imfinzi + LynparzaORION1st-line metastatic non-small cell lung cancer
  • Imfinzi + MEDI0457head and neck squamous cell carcinoma
  • Imfinzi + monalizumabsolid tumours
  • Imfinzi + oleclumabsolid tumours
  • Imfinzi + tremelimumabbiliary tract, oesophageal
  • Imfinzi + tremelimumabgastric cancer
  • Lynparza + adavosertibsolid tumours
  • Lynparza + ceralasertib (AZD6738)VIOLETTEbreast cancer
  • Lynparza + ImfinziMEDIOLAovarian cancer, breast cancer, gastic cancer and small-cell lung cancer
  • MEDI5752solid tumours
  • oleclumab + AZD4635prostate cancer
  • Tagrisso + or selumetinib or savolitinib)TATTONadvanced EGFRm non-small cell lung cancer
  • Tagrisso + savolitinibSAVANNAHadvanced EGFRm non-small cell lung cancer

Phase III

Phase III

  • capivasertib + CTxCAPItello-2901st-line metastatic triple negative breast cancer
  • EnhertuDESTINY-Breast01HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
  • Imfinzi + tremelimumabHIMALAYA1st-line hepatocellular carcinoma
  • Imfinzi + tremelimumabKESTREL1st-line head and neck squamous cell carcinoma
  • Imfinzi + tremelimumab + SoCNILE1st-line urothelial cancer
  • Imfinzi +/- tremelimumab + CRTADRIATIC1st-line limited-stage small-cell lung cancer
  • Imfinzi +/- tremelimumab + CTxPOSEIDON1st-line non-small cell lung cancer
  • Koselugo (selumetinib)SPRINTpaediatric neurofibromatosis type-1
  • Lumoxiti3rd-line hairy cell leukaemia
  • Lynparza + Imfinzi + bevacizumabDUO-O1st-line ovarian cancer

LCM Projects

LCM Projects

  • CalquenceECHO1st-line mantle cell lymphoma
  • CalquenceASCENDrelapsed/refractory chronic lymphocytic leukaemia
  • CalquenceELEVATE-RRrelapsed/refractory chronic lymphocytic leukaemia, high risk
  • CalquenceELEVATE-TN1st-line chronic lymphocytic leukaemia
  • Calquence + venetoclax + obinutuzumab1st-line chronic lymphocytic leukaemia
  • EnhertuHER2-Over-Expressing or -Mutated, Unresectable and/or Metastatic Non Small Cell Lung Cancer
  • EnhertuDESTINY-Breast03HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane
  • EnhertuDESTINY-CRC01HER2-expressing advanced colorectal cancer
  • EnhertuDESTINY-Gastric01HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma patients who have progressed on two prior treatment regimens
  • EnhertuDESTINY-Gastric02HER2-positive gastric cancer that cannot be surgically removed or has spread
  • EnhertuDESTINY-Breast02HER2-positive, Unresectable and/or Metastatic Breast Cancer Pretreated With Prior Standard of Care HER2 Therapies, Including T-DM1
  • EnhertuDESTINY-Breast04HER2-low, unresectable and/or metastatic breast cancer subjects
  • ImfinziCALLAlocally-advanced cervical cancer
  • ImfinziPOTOMACnon muscle invasive bladder cancer
  • ImfinziPACIFIClocally advanced (stage III) NSCLC
  • Imfinzisolid tumours
  • ImfinziPEARL1st-line metastatic non-small cell lung cancer
  • Imfinzi (platform)BEGONIA1st-line metastatic triple negative breast cancer
  • Imfinzi (platform)MAGELLAN1st-line metastatic non-small cell lung cancer
  • Imfinzi + azacitidinemyelodysplastic syndrome
  • Imfinzi + CRTPACIFIC-2locally-advanced (stage III) NSCLC
  • Imfinzi + CRTPACIFIC-5 (China)locally-advanced (stage III) NSCLC
  • Imfinzi + CTxNIAGARAmuscle invasive bladder cancer
  • Imfinzi + CTxTOPAZ-11st-line biliary tract cancer
  • Imfinzi + CTx neoadjuvantAEGEANlocally-advanced (stage I-III) NSCLC
  • Imfinzi + SoCCASPIAN1st-line extensive-stage small-cell lung cancer
  • Imfinzi + VEGFEMERALD-2adjuvant hepatocellular carcinoma
  • Imfinzi + VEGF + TACEEMERALD-1locoregional hepatocellular carcinoma
  • Imfinzi post-SBRTPACIFIC-4stage I/II non-small cell lung cancer
  • LynparzaPROfoundprostate cancer
  • LynparzaSOLO-11st-line BRCAm ovarian cancer
  • LynparzaSOLO-22nd-line or greater BRCAm PSR ovarian cancer, maintenance monotherapy
  • LynparzaOlympiAgBRCA adjuvant breast cancer
  • LynparzaOlympiADgBRCA metastatic breast cancer
  • LynparzaPOLOpancreatic cancer
  • LynparzaSOLO-3gBRCA PSR ovarian cancer
  • Lynparza (basket)MK-7339-002 / LYNK002HRRm cancer
  • Lynparza + abirateronePROpelprostate cancer
  • Lynparza + cediranibCONCERTOrecurrent platinum-resistant ovarian cancer
  • TagrissoADAURAadjuvant EGFRm non-small cell lung cancer
  • TagrissoLAURAstage 3 EGFRm non-small cell lung cancer
  • Tagrisso + CTxFLAURA21st-line advanced EGFRm non-small cell lung cancer

Our Oncology medicines

Our Oncology medicines

2020欧洲杯体育足球滚球比分We cannot provide detailed information about our prescription medicines on this website, in compliance with regulations. Our medicines are approved in individual countries for specific uses and the information we provide for patients is governed by local regulations. In some cases, health care professionals and patients can visit local AstraZeneca websites to find out more about our medicines. Please note that in some countries we are not allowed to provide very much, or sometimes any, information on our prescription medicines so you should seek alternative trustworthy sources. Always ask a healthcare professional for advice about medicines.





Casodex, Cosudex













goserelin acetate implant

Our Resources


1.   Leone RD, Emens LA. Targeting adenosine for cancer immunotherapy. J Immunother Cancer. 2018;6:57. .

2.     McGowan CH, Russell P. Human Wee 1 kinase inhibits cell division by phosphorylating p34cdc2 exclusively on Tyr15. EMBO J. 1993 Jan; 12(1):75-85.

3.     Tominaga Y, Li C, Wang RH, Deng CX. Murine Wee1 plays a critical role in cell cycle regulation and preimplantation stages of embryonic development. J Biol Sci. 2006; 2(4):161-170.

4.     Guertin AD, Li J, Liu Y, et al. Preclinical evaluation of the Wee-1 inhibitor MK-1775 as a single-agent anticancer therapy. Mol Cancer Ther. 2013 Aug;12(8):1442-1452.

5.     Do K, Doroshow JH, Kummar S. Wee1 kinase as a target for cancer therapy. Cell Cycle. 2013 Oct 1; 12(19), 3159-3164.

6.     Hirai H, Iwasawa Y, Okada M, et al. Small-molecule inhibition of Wee-1 kinase by MK-1775 selectively sensitizes p53-edficient tumor cells to DNA-damaging agents. Mol Cancer Ther. 2009 Nov; 8(11):2992-3000.

7.     Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005 Nov 14;24(50):7455-7464.

8.     Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-644.

9.     Clark AS, West K Streicher S, Dennis PA. Constitutive and inducible AKT activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther. 2002 Jul;1(9):707-717.

10.  Huang W-C, Hung M-C. Induction of AKT activity by chemotherapy confers acquired resistance. J Formos Med Assoc. 2009 Mar;108(3):180-194.

11.  Selli, C., et al. Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers. Breast Cancer Res. 2016; 18: 118 .

12.  Basaran GA, et al. Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer. Cancer Treat Rev. 2018;63:144-155..

13.  Mitri, Z. et al. The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy. Chemother Res Pract. 2012; 2012: 743193. doi: 10.1155/2012/743193. Accessed April 2019.

14.  Carlson B. HER2 TESTS: How Do We Choose? Biotechnol Healthc. 2008; 5(3): 23–27.

15.  The Royal Marsden NHS Foundation Trust. A beginner’s guide to BRCA1 and BRCA2. Available at: http://www.royalmarsden.nhs.uk/sites/default/files/files_trust/beginners-guide-to-brca1-andbrca2.PDF. Accessed May 2019.


Veeva ID: Z4-22142  
Date of Prep: March 2020
Date of Expiry: March 2022